Filtered By:
Drug: Pravastatin
Education: Study

This page shows you your search results in order of date.

Order by Relevance | Date

Total 38 results found since Jan 2013.

Pharmacological interventions for asymptomatic carotid stenosis
CONCLUSIONS: Although there is no high-certainty evidence to support pharmacological intervention, this does not mean that pharmacological treatments are ineffective in preventing ischaemic cerebral events, morbidity, and mortality. High-quality RCTs are needed to better inform the best medical treatment that may reduce the burden of carotid stenosis. In the interim, clinicians will have to use other sources of information.PMID:37565307 | PMC:PMC10401652 | DOI:10.1002/14651858.CD013573.pub2
Source: Atherosclerosis - August 11, 2023 Category: Cardiology Authors: Caroline Nb Clezar Carolina Dq Flumignan Nicolle Cassola Luis Cu Nakano Virginia Fm Trevisani Ronald Lg Flumignan Source Type: research

Protective Effects of Different Classes, Intensity, Cumulative Dose-Dependent of Statins Against Primary Ischemic Stroke in Patients with Type 2 Diabetes Mellitus
Curr Atheroscler Rep. 2023 Jul 29. doi: 10.1007/s11883-023-01135-w. Online ahead of print.ABSTRACTPURPOSE OF REVIEW: The aim of this study is to investigate the protective effects of different statin classes, intensity, and cumulative dose-dependent against primary ischemic stroke in patients with T2DM.RECENT FINDINGS: The Cox hazards model was used to evaluate statin use on primary ischemic stroke. Case group: T2DM patients who received statins; control group: T2DM patients who received no statins during the follow-up. Adjusted hazard ratio (aHR) for primary ischemic stroke was 0.45 (95% CI: 0.44 to 0.46). Cox regression ...
Source: Cancer Control - July 29, 2023 Category: Cancer & Oncology Authors: Jung-Min Yu Wan-Ming Chen Ben-Chang Shia Szu-Yuan Wu Source Type: research

Does aspirin have a place in primary cardiovascular prevention by the polypill  ? Simulation study on a realistic virtual population
CONCLUSION: Until proven otherwise, aspirin has only a limited place in individuals between 35 and 65 years without a cardiovascular history. We showed how simulating therapeutic strategies on a realistic virtual population could be used for best applying available evidence.PMID:36841655 | DOI:10.1016/j.therap.2023.01.011
Source: Therapie - February 25, 2023 Category: Psychiatry & Psychology Authors: Mor Fall Guillaume Grenet Hai-Ha Le Behrouz Kassa ï Jean-Christophe Lega R émy Boussageon Sabine Mainbourg Ivanny Marchant Johanne Gafsi Amadou Moctar Dieye Fran çois Gueyffier Source Type: research

Statin Therapy in Ischemic Stroke Models: A Meta-Analysis
AbstractStatins, drugs known for lipid lowering capabilities and reduction of cardiovascular disease, have demonstrated neuroprotective effects following ischemic stroke in retrospective clinical and animal studies. However, dosing (methods, time, type of statin, and quantity) varies across studies, limiting the clinical applicability of these findings. Furthermore, a comprehensive review of statins in edema and blood-brain barrier (BBB) breakdown is needed to provide insight on diverse, less explored neuroprotective effects. In the present study, we conduct a meta-analysis of publications evaluating statin administration ...
Source: Translational Stroke Research - December 1, 2019 Category: Neurology Source Type: research

Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at “Extreme” ASCVD Risk
AbstractPurpose of ReviewTo review randomized interventional clinical and imaging trials that support lower targeted atherogenic lipoprotein cholesterol goals in “extreme” and “very high” atherosclerotic cardiovascular disease (ASCVD) risk settings. Major atherosclerotic cardiovascular event (MACE) prevention among the highest risk patients with ASCVD requires aggressive management of global risks, including lowering of the fundamental atherogenic ap olipoprotein B-associated lipoprotein cholesterol particles [i.e., triglyceride-rich lipoprotein remnant cholesterol, low-density lipoprotein cholesterol (LDL-C), and ...
Source: Current Diabetes Reports - November 20, 2019 Category: Endocrinology Source Type: research

Effect of Statin on Stroke Recurrence Prevention at Different Infarction Locations: A Post Hoc Analysis of The J-STARS Study.
CONCLUSIONS: Pravastatin significantly reduced the recurrence rate of all stroke among patients with PCS. Thus, the effect of statin on the recurrence of stroke may differ according to infarction location. PMID: 31554765 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - September 27, 2019 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

Different Influences of Statin Treatment in Preventing At-Risk Stroke Subtypes: A Post Hoc Analysis of J-STARS.
CONCLUSIONS: Statins showed different influences on the risks of atherothromobotic and lacunar stroke according to postrandomized LDL cholesterol levels. PMID: 31534062 [PubMed - as supplied by publisher]
Source: Journal of Atherosclerosis and Thrombosis - September 20, 2019 Category: Cardiology Tags: J Atheroscler Thromb Source Type: research

New Biomarkers for Atherothrombosis in Antiphospholipid Syndrome: Genomics and Epigenetics Approaches
Conclusions In recent years, there have been many advances in the understanding of the molecular basis for vascular involvement in APS, but many areas need to be further investigated, in particular the association between altered genetic/epigenetic profiles, autoantibodies and clinical manifestations, and the effectiveness of new therapeutic strategies. It would be interesting to apply next generation sequencing technologies like RNA-Seq along with GWAS to screen both, the gene profile and the whole transcriptome of large cohorts of primary APS patients, in order to reveal the mutations/polymorphisms, post-transcriptiona...
Source: Frontiers in Immunology - April 15, 2019 Category: Allergy & Immunology Source Type: research

Statins in Ischemic Stroke Prevention: What Have We Learned in the Post-SPARCL (The Stroke Prevention by Aggressive Reduction in Cholesterol Levels) Decade?
We describe the current status of lipid-lowering therapies for ischemic stroke prevention. The SPARCL trial published in 2006 has been a landmark study in vascular neurology. The trial demonstrated that high-dose atorvastatin prevents recurrent stroke, and led the AHA/ASA to recommend statin therapy for patients with stroke or TIA of atherosclerotic origin.Recent findingsRecently, the J-STARS study demonstrated that therapy with low-dose pravastatin reduced atherothrombotic infarction incidence among patients with prior ischemic stroke. Besides, several trials have shown improved stroke outcomes with non-statin lipid-lower...
Source: Current Treatment Options in Neurology - April 7, 2019 Category: Neurology Source Type: research